Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.

The New England journal of medicine - 2 Jan 2025

Wolchok Jedd D, Chiarion-Sileni Vanna, Rutkowski Piotr, Cowey C Lance, Schadendorf Dirk, Wagstaff John, Queirolo Paola, Dummer Reinhard, Butler Marcus O, Hill Andrew G, Postow Michael A, Gaudy-Marqueste Caroline, Medina Theresa, Lao Christopher D, Walker John, Márquez-Rodas Iván, Haanen John B A G, Guidoboni Massimo, Maio Michele, Schöffski Patrick, Carlino Matteo S, Sandhu Shahneen, Lebbé Céleste, Ascierto Paolo A, Long Georgina V, Ritchings Corey, Nassar Ayman, Askelson Margarita, Benito Melanie Pe, Wang Wenjia, Hodi F Stephen, Larkin James

Abstract excerpt

BACKGROUND: Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given that patients with advanced melanoma are living longer than 7.5 years, longer-term data were needed to address new clinically relevant questions. METHODS: We randomly assigned patients...

Topics

Join the communities discussing this publication.

Antineoplastic Combined Chemotherapy Protocols
Double-Blind Method
Ipilimumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Kaplan-Meier Estimate

Progression-Free Survival

Source

Identifiers

PMID: 39282897
DOI: 10.1056/NEJMoa2407417

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.PMID 39282897Read ↗

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.Semantic proximity Read ↗

Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trialSemantic proximity Read ↗

Nivolumab in Previously Untreated Melanoma without BRAF MutationSemantic proximity Read ↗

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.Semantic proximity Read ↗

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.Semantic proximity Read ↗

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.Semantic proximity Read ↗

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.Semantic proximity Read ↗

FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma.Semantic proximity Read ↗

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.Semantic proximity Read ↗

The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.Semantic proximity Read ↗

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.Semantic proximity Read ↗

Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.